• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexeo Therapeutics, Inc. - Common Stock (NQ: LXEO )

    7.805 -0.145 (-1.82%)
    Streaming Delayed Price Updated: 12:07 PM EST, Nov 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lexeo Therapeutics, Inc. - Common Stock

    LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024
    LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results
    Via Benzinga
    Exposures Fossil Fuels
    Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
    Via Benzinga
    Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
    The company is in the early stages of testing a gene therapy for the heart complications of a genetic disease. 
    Via Investor's Business Daily
    Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics to Participate in Upcoming Investor Conferences
    From Lexeo Therapeutics
    Via GlobeNewswire
    Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
    Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor... 
    From Lexeo Therapeutics
    Via GlobeNewswire
    RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know
    Via Benzinga
    Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
    From Lexeo Therapeutics
    Via GlobeNewswire
    Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
    Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor... 
    From Lexeo Therapeutics
    Via GlobeNewswire
    Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
    U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
    From Lexeo Therapeutics
    Via GlobeNewswire
    Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... 
    Via Benzinga
    Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday
    U.S. stocks traded mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Fastenal Company (NASDAQ: FAST) rose during Thursday’s session after the company reported... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From LEXEO Therapeutics
    Via GlobeNewswire
    Marathon Digital, Canaan, CleanSpark And Other Big Stocks Moving Lower On Tuesday
    U.S. stocks traded higher, with the Dow Jones index gaining around 40 points on Tuesday. Here are some big stocks recording losses in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
    From LEXEO Therapeutics
    Via GlobeNewswire
    LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023
    Lexeo Therapeutics just reported results for the third quarter of 2023. 
    Via InvestorPlace
    Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
    From LEXEO Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Pineapple Financial Drops In Trading Debut
    Shares of Pineapple Financial slipped over 25% in their trading debut following a downsized IPO. The tech-focused mortgage brokerage had cut the size of its offering from 1.25 million to 875,000 common... 
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.